Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CARsgen to Test Claudin18.2 mAb with Roche’s PD-L1 for Gastric Cancer

publication date: Jan 31, 2023

Shanghai CARsgen Therapeutics and Roche formed a collaboration to test a combination of CARsgen’s Claudin18.2-targeting mAb and Roche’s atezolizumab, a PD-L1 checkpoint inhibitor, in patients with gastric cancer. Most of CARgen’s focus is on CAR-T candidates (including a Claudin18.2 CAR-T), but it is also developing a single mAb candidate -- AB011. Roche will be responsible for the co-funded study, using its Morpheus Platform, a collection of Phase Ib/II clinical trials designed to address cancers with high unmet needs. The two companies will co-share the costs of the AB011 treatment arms. More details....

Stock Symbol: (HK: 2171)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital